Vaccines News and Research RSS Feed - Vaccines News and Research

Scientists chemically synthesize ECA-derived oligosaccharides relevant for immunotherapy

Scientists chemically synthesize ECA-derived oligosaccharides relevant for immunotherapy

Immunotherapy using monoclonal antibodies is a promising treatment strategy, and it might now be within reach: American scientists have successfully prepared an oligosaccharide enterobacterial antigen for which a monoclonal antibody has been developed. The study is published in the journal Angewandte Chemie. [More]
Study shows why candidate vaccine used in HVTN 505 clinical trial not protective against HIV infection

Study shows why candidate vaccine used in HVTN 505 clinical trial not protective against HIV infection

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection despite robustly inducing anti-HIV antibodies: the vaccine stimulated antibodies that recognized HIV as well as microbes commonly found in the intestinal tract, part of the body's microbiome. [More]
Researchers uncover master regulators that govern the fate of TFH cells

Researchers uncover master regulators that govern the fate of TFH cells

Follicular helper Tcells (TFH cells), a rare type of immune cell that is essential for inducing a strong and lasting antibody response to viruses and other microbes, have garnered intense interest in recent years but the molecular signals that drive their differentiation had remained unclear. [More]
ACP supports for eliminating non-medical vaccination exemptions

ACP supports for eliminating non-medical vaccination exemptions

Support for eliminating existing exemptions, except for medical reasons, from immunization laws was among the policy recommendations adopted last weekend at the summer meeting of the Board of Regents of the American College of Physicians. [More]
New white paper provides overview of factors that drive vaccination underutilization in older adults

New white paper provides overview of factors that drive vaccination underutilization in older adults

Today the nonprofit Alliance for Aging Research released a white paper, Our Best Shot: Expanding Prevention through Vaccination in Older Adults, that provides a comprehensive overview of the factors that drive vaccination underutilization in seniors and offers recommendations on how industry, government, and health care experts can improve patient compliance. [More]
LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

LixiLan-O Phase III clinical trial meets primary endpoint in patients with type 2 diabetes

Sanofi announced today that the LixiLan-O Phase III clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL. [More]
Two-step regimen of experimental MERS vaccines show promise in mice

Two-step regimen of experimental MERS vaccines show promise in mice

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. Vaccinated mice produced broadly neutralizing antibodies against multiple strains of the MERS coronavirus (MERS-CoV), while vaccinated macaques were protected from severe lung damage when later exposed to MERS-CoV. [More]
Study elucidates on global prevalence of chronic hepatitis B infections

Study elucidates on global prevalence of chronic hepatitis B infections

Hepatitis B infections are among the most common infectious diseases worldwide. The disease can become chronic, and is one of the most important causes of severe diseases such as liver cancer. In the scope of an international study funded by the World Health Organization, scientists from the Helmholtz Centre for Infection Research in Braunschweig determined how often the chronic infection occurs in different countries and how many people of the general population are affected. They noted strong differences between different countries. [More]
German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

German life sciences entrepreneurs granted option to develop Aeterna Zentaris’ oral allogenic tumor vaccine technology

Aeterna Zentaris Inc. today announced that it has granted to German life sciences entrepreneurs with a proven track-record of funding the development and commercialization of biotechnology, an option to license the Company's live recombinant oral allogenic tumor vaccine technology, including AEZS-120, the most advanced product candidate for prostate cancer which is ready to enter a Phase 1 clinical trial. [More]
Cincinnati Children's doctors remind parents about the importance of immunizing kids before sending them to school

Cincinnati Children's doctors remind parents about the importance of immunizing kids before sending them to school

Doctors at Cincinnati Children's Hospital Medical Center want to remind parents about the importance of immunizing their children when preparing to send their children back to school. [More]

Leishmania-fighting immune cells that linger after initial infections help ward off secondary attack

Immune cells that hang around after parasitic skin infection help ward off secondary attack, according to a study in The Journal of Experimental Medicine. These skin squatters may prove to be the key to successful anti-parasite vaccines. [More]
Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron, Sanofi to jointly advance new immuno-oncology treatment options for cancer patients

Regeneron Pharmaceuticals, Inc. and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. [More]
New moms don't receive advice on infant care from physicians, study finds

New moms don't receive advice on infant care from physicians, study finds

Many new mothers do not receive advice from physicians on aspects of infant care such as sleep position, breastfeeding, immunization and pacifier use, according to a study funded by the National Institutes of Health. [More]
Twenty Radboud researchers receive Veni grant as part of Innovational Research Incentives Scheme

Twenty Radboud researchers receive Veni grant as part of Innovational Research Incentives Scheme

Twenty young and promising researchers from Nijmegen - eleven from Radboud University and nine from Radboudumc - are each to receive up to 250,000. NWO (The Netherlands Organisation for Scientific Research) is awarding the Veni grant as part of the Innovational Research Incentives Scheme. [More]
FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

FDA approves Praluent (alirocumab) Injection for treatment of patients with high LDL cholesterol

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration approved Praluent (alirocumab) Injection, the first FDA-approved treatment in a new class of drugs known as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. [More]
EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

EMA's CHMP recommends approval of Praluent (alirocumab) for use in patients with hypercholesterolemia

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for the marketing authorization of Praluent (alirocumab), recommending its approval for use in certain adult patients with hypercholesterolemia. [More]
Aggressive vaccination effort reduces transmission of measles among North American Amish communities

Aggressive vaccination effort reduces transmission of measles among North American Amish communities

An aggressive vaccination effort in response to the 2014 measles outbreak among North American Amish communities in Ohio significantly reduced the transmission of measles and the expected number of cases, according to a new study, even though under-vaccination among the North American Amish and in other communities around the United States led to the highest national annual number of reported cases in 2014 in the last 20 years. [More]
TSRI awarded two grants to support development of effective vaccine against HIV/AIDS

TSRI awarded two grants to support development of effective vaccine against HIV/AIDS

The Scripps Research Institute has been awarded two grants from the Bill & Melinda Gates Foundation totaling more than $4.5 million to fund efforts to develop a vaccine against HIV/AIDS. [More]
SutroVax completes $22 million Series A financing

SutroVax completes $22 million Series A financing

SutroVax, a recently established biopharmaceutical vaccine company, today announced the completion of a $22 million Series A financing. SutroVax is developing vaccines for infectious disease targets, with an initial emphasis on best-in-class conjugate vaccines, using an exclusive license to Sutro Biopharma's Xpress CF and Xpress CF+ platforms for cell free protein synthesis and site-specific conjugation respectively. [More]
Southampton scientists set to analyse investments into infectious disease research

Southampton scientists set to analyse investments into infectious disease research

Scientists at the University of Southampton are set to analyse research investments into infectious disease research, particularly pneumonia and maternal and neonatal infections, after receiving over £370,000 in funding from the Bill & Melinda Gates Foundation. [More]
Advertisement
Advertisement